备孕、怀孕期间服用司美格鲁肽安全吗？一文看懂！

Core Viewpoint - The article discusses the safety and recommendations regarding the use of GLP-1 medications during pregnancy and breastfeeding, highlighting the need for caution and further research in this area [4][6][12]. Summary by Sections GLP-1 Medications and Pregnancy - GLP-1 receptor agonists, such as Ozempic (semaglutide) and Trulicity (dulaglutide), are increasingly used for treating type 2 diabetes and weight management, but their safety during pregnancy is uncertain [4]. - Experts recommend that women stop or delay the use of GLP-1 medications if they are pregnant or planning to become pregnant [6]. Research on GLP-1 Use During Pregnancy - A large study published in January 2024 in JAMA Internal Medicine tracked around 50,000 children born to mothers with type 2 diabetes who used GLP-1 or insulin during early pregnancy, finding no increased risk of congenital defects compared to insulin use [7]. - Another study in 2023 reviewed 39 independent studies and suggested that GLP-1 use might affect fetal weight and growth, recommending avoidance during pregnancy due to limited human data [8]. Risks Associated with GLP-1 Use During Pregnancy - Potential risks of GLP-1 medications during pregnancy include miscarriage, low birth weight, and congenital defects, primarily based on animal studies [9]. - Current evidence suggests minimal risk if GLP-1 is used in early pregnancy, but healthcare providers may recommend switching to safer alternatives [9]. Recommendations for Women Planning Pregnancy - It is advised to stop using GLP-1 medications at least two months before attempting to conceive, along with adopting healthy lifestyle measures [11]. - The CDC recommends additional preconception measures for women with diabetes to increase the chances of a healthy pregnancy [11]. Breastfeeding and GLP-1 Medications - There is insufficient research on the safety of GLP-1 medications during breastfeeding, and current recommendations suggest avoiding their use during this period [12].